Ginkgo Bioworks Holdings Stock (NYSE: DNA)

Dernières nouvelles pour Ginkgo Bioworks Holdings (NYSE:DNA) Stock

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

Trading Ideas

DEVS

DevvStream Shares Resume Trade Following Circuit Breaker Halt

The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells
AbCellera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the ‘408 Patent"). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells.
Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the ‘408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's ‘408 Patent are valid. AbCellera's ‘408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California.

News

Legal

ABCL

BRKR

AbCellera Announces The Federal Circuit Upholds Validity Of Its '408 Patent On Microfluidic Cell-Culturing Devices, Rejecting Bruker Cellular's Invalidity Challenge And Strengthening AbCellera's Position In Ongoing Patent Litigation.

Bill Gates, the co-founder of Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and a tech industry titan, recently announced plans to give away 99% of his wealth by 2045, but not everyone is convinced.&nbsp;
The billionaire, who became the world's youngest <a href="https://www.benzinga.com/startups/24/12/42419457/bill-gates-billionaire-success-was-fueled-by-a-crucial-childhood-habit-thats-nearly-extinct-today-heres-why-thats-a-problem">self-made billionaire</a> at age 31 in 1987 and the first centibillionaire in 1999, currently holds a net worth of $113 billion, making him the 13th-richest person in the world, according to Forbes.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">A Billionaire&#8217;s Bold Promise</h2>
The 69-year-old philanthropist outlined his latest giving pledge in a <a href="https://www.gatesnotes.com/home/home-page-topic/reader/n20-years-to-give-away-virtually-all-my-wealth">blog post</a>, declaring that his Bill &amp; Melinda Gates Foundation will <a href="https://www.benzinga.com/markets/25/05/45286464/bill-gates-commits-99-of-his-remaining-fortune-to-gates-foundation-set-to-wind-down-in-20-years-somebody-should-give-more-money-than-i-did">wind down its operations by 2045</a>, aiming to donate another $200 billion in that time.&nbsp;
Gates, who once held the title of the world's richest person for 18 of 24 years between 1995 and 2017, said he does not want to be remembered as someone who "died rich."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I&#39;ve been hearing this for 15 years and every year Bill has more. <a href="https://t.co/QTRw6zdMuE">https://t.co/QTRw6zdMuE</a>
&mdash; Coffeezilla (@coffeebreak_YT) <a href="https://twitter.com/coffeebreak_YT/status/1920723618482327789?ref_src=twsrc%5Etfw">May 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
However, the response online has been mixed. Popular YouTuber Stephen Findeisen, better known as Coffeezilla, was among those expressing doubt, <a href="https://x.com/coffeebreak_YT/status/1920723618482327789">posting on X</a>, "I've been hearing this for 15 years and every year Bill has more." The post got a lot of similar responses, with some questioning if Gates&#8217; promise is about real giving or just maintaining influence.
"They're likely just putting it into a trust and then ‘giving it away' over the course of 50-100 years," one commenter, Sam Tayyari, <a href="https://x.com/samtayyari/status/1920724915323306365">suggested</a>, adding that many charities "spend a lot on ‘administrative costs' like private jetting to give a 10 min speech while staying in $10k/night resorts."
Others pointed out that even giving away 99% of his fortune would still leave Gates a billionaire, with one user <a href="https://x.com/im_deiting/status/1920724966871314829">noting</a>, "1% of $200 billion is $2 billion. That&#8217;s a lot of money too."
Critics also drew comparisons to other wealthy figures, like George Soros, who have faced similar skepticism about their charitable efforts. One commenter <a href="https://x.com/Mountain_Texan/status/1920724460199412109">argued</a>, "It's meaningless anyway. He's going to ‘give it away' in the same way Soros gave his money away. He's purchasing influence, not giving money away."
See Also: <a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a>
Gates, who has said he was inspired by <a href="https://www.benzinga.com/personal-finance/25/05/45240439/ive-made-no-sacrifice-warren-buffett-has-given-away-60-billion-but-says-giving-time-is-more-admirable-ive-done-little-of-that">philanthropists like Warren Buffett</a> and 19th-century industrialist Andrew Carnegie, acknowledged that his approach to giving is about urgency.&nbsp;
In a recent BBC <a href="https://www.bbc.com/news/articles/cx2e87lzqkdo">interview</a>, he said, "It's really about the urgency. We can spend a lot more if we're not trying to be perpetual, and I know that the spending will be in line with my values."
According to Gates, the foundation has already distributed $100 billion for health and development projects and plans to spend another $200 billion in the coming decades, depending on markets and inflation. However, critics argue that the true impact of these donations can be difficult to measure, given the scale of his wealth and the complex structures often used in philanthropy.
Despite the skepticism, Gates remains committed to his vision, saying in his blog post, "People will say a lot of things about me when I die, but I am determined that ‘he died rich' will not be one of them."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

MSFT

Popular YouTuber Coffeezilla Is Puzzled By Bill Gates' Philanthropy Plans—'I've Been Hearing This For 15 Years And Every Year Bill Has More'

WIIM

SATS

EchoStar shares are trading lower following a report suggesting that the FCC told chairman and co-founder Charlie Ergen that the agency staff would investigate the company's compliance with federal requirements to build a 5G network.

Cryptocurrency markets are down on Monday after Bitcoin peaked above $105,000 in early trading hours.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$102,002.91</td>
<td>-2.5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,459.63</td>
<td>-2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$170.91</td>
<td>-1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.48</td>
<td>-4.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2274</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001542</td>
<td>-3.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 3% and daily active addresses falling by 7.4%. Transactions greater than $100,000 are down from 9,463 to 8,934 in a single day. Exchanges netflows are down by 388.7%.</li>
<li>Coinglass data reports 178,950 traders were liquidated in the past 24 hours for $556.54 million. Bitcoin long liquidations spiked to the highest level since April 7.</li>
<li>Bitcoin held by U.S. spot ETFs has climbed to 1.175 million BTC, just 6,500 BTC shy of its all-time high of 1.182 million, according to Glassnode <a href="https://x.com/glassnode/status/1921911197198090255">data</a>.</li>
<li>Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1921943951268819201">reports</a> Bitcoin miners having realized over $10.37 million in profits, signaling improved miner profitability.</li>
<li>Sentora <a href="https://x.com/SentoraHQ/status/1921969105332023660">notes</a> that after Bitcoin surpassed $100,000, exchange flows turned sharply negative with $550 million in BTC withdrawn on Friday alone, indicating strong accumulation by investors.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45344230/exclusive-defi-development-makes-record-solana-purchase-surpasses-100-million-in-treasury-holdings">EXCLUSIVE: DeFi Development Makes Record Solana Purchase, Surpasses $100 Million In Treasury Holdings</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354779/stanford-warns-future-of-crypto-depends-on-regulation-quantum-safe-systems-digital-dollar-competition">Stanford Warns Future Of Crypto Depends On Regulation, Quantum-Safe Systems, Digital Dollar Competition</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45355405/coinbases-subscription-gains-deribit-acquisition-blockchain-revenue-strength-prompt-analyst-support">Coinbase&#8217;s Subscription Gains, Deribit Acquisition, Blockchain Revenue Strength Prompt Analyst Support</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">Nakamoto Holdings Raises $710M, Merges With KindlyMD To Build Bitcoin Treasury Holding Company</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45349057/strategy-buys-134b-in-bitcoin-at-99856-cites-155-btc-yield">Strategy Buys $1.34B In Bitcoin At $99,856, Cites 15.5% BTC Yield</a></li>
<li><a href="https://www.benzinga.com/markets/25/05/45349144/billionaire-tim-draper-says-businesses-that-are-not-holding-bitcoin-in-their-treasuries-are-being-ir">Billionaire Tim Draper Says Businesses That Are Not Holding Bitcoin In Their Treasuries Are &#8216;Being Irresponsible&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45340929/cathie-wood-highlights-analysts-take-more-than-humans-crypto-was-made-for-ai">Cathie Wood Highlights Analyst&#8217;s Take: &#8216;More Than Humans, Crypto Was Made For AI&#8217;</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>$1.11</td>
<td>+23.8%</td>
</tr>
<tr>
<td>Four (CRYPTO: FORM)</td>
<td>$2.78</td>
<td>+17.6%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.48&nbsp;</td>
<td>+4.6%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Altcoin Sherpa remains bullish on Bitcoin long-term but warns of a likely pullback in the short term, though the timing and depth remain unclear.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">im still bullish <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> but I&#39;m still going to keep posting this chart as a reminder to myself and others that we &#x2A;probably&#x2A; see some sort of pullback soon (in theory). I&#39;m not sure when/how deep but yeah. <a href="https://t.co/gR36Bgn6eV">https://t.co/gR36Bgn6eV</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1921968703727419659?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Voicing a similar opinion, Sherpa <a href="https://x.com/AltcoinSherpa/status/1921973201770332279">advised</a> that if anyone is looking to buy Bitcoin for long-term positions and aren&#8217;t very active, it&#8217;s probably best to wait for a dip, potentially to the low to mid $90,000s.
ShardiB2 <a href="https://x.com/ShardiB2/status/1921979353820225736">points </a>to $103,400 as a critical daily close level. A close above would invalidate a potential local top, but advises caution for longs at current levels, noting higher time frame signals are more reliable. 
Meanwhile, Kaleo speculates whether Bitcoin is positioning itself for a massive upside scenario, potentially spiking to $520,000 in the longer term.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> / <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Are you ready for this scenario? <a href="https://t.co/PxHMB3Xzso">pic.twitter.com/PxHMB3Xzso</a>
&mdash; K A L E O (@CryptoKaleo) <a href="https://twitter.com/CryptoKaleo/status/1921979557348810813?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Cryptomist <a href="https://x.com/Thecryptomist/status/1921956911454323107">sees</a> Bitcoin CME gap having been filled, and the user now expects BTC to move toward $108,000. Altcoins are anticipated to follow the upward move.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$DOGE

$ETH

$SHIB

$SOL

$WIF

$XRP

Bitcoin, Ethereum, Dogecoin Slip While XRP Holds Firm: Is A Pullback Coming?

Shares of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) soared 8.1% to $208.68 Monday afternoon after the U.S. and China <a href="https://www.benzinga.com/government/regulations/25/05/45355655/magnificent-seven-gain-700b-after-us-china-slash-tariffs-gold-crashes-whats-driving-markets-monday">announced</a> a temporary easing of tariffs, marking a significant step toward de-escalating long-standing trade tensions. The move lifted investor sentiment across sectors and boosted shares of companies heavily reliant on global supply chains.
What To Know: Amazon stands to benefit directly from the tariff reprieve. As one of the world's largest e-commerce and cloud services companies, Amazon is deeply integrated with global manufacturing, particularly in <a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs">China</a>.
Read Also: <a href="https://www.benzinga.com/news/25/05/45355529/needham-says-draftkings-dkng-q1-handle-should-calm-fears">Needham Says DraftKings Q1 Handle Should &#8216;Calm Fears&#8217;</a>
Many of the products sold on Amazon's marketplace—including electronics, consumer goods and private-label brands—are sourced or assembled in Chinese factories. Lower import tariffs reduce the company's cost of goods sold, improving profit margins across its retail segment.
Additionally, Amazon Web Services could gain ground in international markets amid improving geopolitical relations, as fewer regulatory frictions may ease data localization pressures and expand enterprise cloud adoption in Asia.
Beyond its direct exposure, Amazon's stock rise also reflects <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">broader bullish sentiment</a> in tech during Monday&#8217;s session. With global supply chains potentially stabilizing and trade risk easing, investors could be pricing in stronger revenue growth, improved logistics and greater consumer confidence heading into the second half of the year.
Read Also: <a href="https://www.benzinga.com/news/25/05/45354368/why-marvell-technology-mrvl-stock-is-soaring-today">Why Marvell Technology Stock Is Soaring Today</a>
<h2 class="wp-block-heading">How To Buy AMZN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Amazon&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMZN has a 52-week high of $242.52 and a 52-week low of $151.61.

AMZN

Amazon (AMZN) Stock Soars 8% Monday: What's Going On?

Goldman Sachs analyst Michael Ng <a target="_blank" href="https://www.benzinga.com/quote/PARA/analyst-ratings" rel="noreferrer noopener">remained Not Rated</a> on Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) on Friday.
Revenue of $7.19 billion beat Ng and consensus estimate of $7.04 billion and $7.1 billion.
Adjusted OIBDA of $688 million beat $652 million and $666 million Ng and consensus estimate driven by a broad-based beat across DTC, TV Media, and Film.
Also Read: <a href="https://www.benzinga.com/25/03/44120055/paramount-gains-engagement-but-tv-and-film-struggles-lead-to-analyst-outlook-revision" target="_blank" rel="noreferrer noopener">Paramount Faces PayTV Declines, But Streaming And Licensing Gains Prompt Analyst Estimate Revisions</a>
TV Media advertising was flat on an underlying basis on Super Bowl comps, helped by strong sports programming like March Madness and the NFL Playoffs.
Like Warner Bros. Discovery, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), advertising outperformed, and there has been limited discernible impact from macro uncertainty, Ng noted.
DTC advertising declined 1% on an underlying basis on Super Bowl comps, which should continue throughout 2025, driven by growing industry AVOD supply (e.g., Amazon.Com Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>)) as per the analyst.
The analyst remarked that Paramount expects the proposed Skydance acquisition to close in the first half of 2025. Free cash flow of $123 million beat the analyst&#8217;s estimate of $69 million and $13 million.
DTC revenue of $2.04 billion missed the consensus estimates of $2.1 billion and $2.09 billion, with OIBDA of $(109) million above the analyst and the consensus estimates of $(128) million and $(153) million. Paramount+ subscribers increased to 79.0 million (versus Ng&#8217;s estimate of 78.6 million), and global Paramount+ revenue grew 16% (versus Ng&#8217;s estimate of +12%).
TV Media revenue of $4.54 billion beat Ng and consensus estimate of $4.39 billion and $4.43 billion, with OIBDA of $922 million beating Ng estimate of $904 million but missing consensus of $951 million.
Filmed Entertainment revenue of $627 million was above Ng and consensus estimate of $575 million and $610 million, with OIBDA of $20 million beating Ng and consensus estimate of $13 million and $17 million.
Paramount introduced second-quarter guidance including subscriber decline at Paramount+ due to content seasonality and termination of an international bundle, Paramount+ ARPU growth to accelerate off first-quarter 2025, TV Media affiliate revenue decline rates to see similar underlying trends versus first-quarter 2025, TV Media advertising to see similar underlying trends versus first-quarter 2025 in digital while deceleration in linear, OIBDA loss in Studios driven by costs associated with the release of Mission Impossible &#8211; The Final Reckoning and free cash flow to Mirror last year.
Paramount reiterated 2025 guidance, including OIBDA, which will modestly decline, including impacts from the Super Bowl, free cash flow, which will increase, including 2024 Super Bowl and political advertising impacts, and domestic profitability for Paramount+.
The analyst projects fiscal 2025 revenue of $28.7 billion and adjusted EPS of $0.81.
Price Action:&nbsp;PARA stock is up 0.50% by $12.00 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a></li>
</ul>

Analyst Color

Entertainment

Price Target

Analyst Ratings

Tech

Media

PARA

PARAA

Paramount's Super Bowl Boost And Studio Strength Help Offset Streaming Miss: Analyst

Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Humacyte will report an earnings per share (EPS) of $-0.21.
The market awaits Humacyte's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.09, leading to a 0.0% drop in the share price the following trading session.
Here's a look at Humacyte's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.25</td>
<td>-0.25</td>
<td>-0.24</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.33</td>
<td>-0.27</td>
<td>-0.29</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>10.0%</td>
<td>-10.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747077165_0.png" alt="eps graph" />
<h3>Market Performance of Humacyte's Stock</h3>
Shares of Humacyte were trading at $1.19 as of May 09. Over the last 52-week period, shares are down 79.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HUMA/earnings">To track all earnings releases for Humacyte visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

HUMA

Exploring Humacyte's Earnings Expectations

Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Cellectar Biosciences will report an earnings per share (EPS) of $-0.16.
Anticipation surrounds Cellectar Biosciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.34, which was followed by a 5.34% increase in the share price the next day.
Here's a look at Cellectar Biosciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.35</td>
<td>-0.37</td>
<td>-1</td>
<td>-0.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.01</td>
<td>-0.40</td>
<td>-0.18</td>
<td>-0.74</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-9.0%</td>
<td>0.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747077057_0.png" alt="eps graph" />
<h3>Market Performance of Cellectar Biosciences's Stock</h3>
Shares of Cellectar Biosciences were trading at $0.2474 as of May 09. Over the last 52-week period, shares are down 91.9%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CLRB/earnings">To track all earnings releases for Cellectar Biosciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLRB

Insights Ahead: Cellectar Biosciences's Quarterly Earnings

<a href="https://www.biorxiv.org/content/10.1101/2025.05.09.652772v1">https://www.biorxiv.org/content/10.1101/2025.05.09.652772v1</a>

Biotech

General

AEMD

Watching Aethlon Medical; Traders Circulate Article From bioRxiv: "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin (Aethlon Medical's Hemopurifier)"

Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Intellinetics to report an earnings per share (EPS) of $-0.07.
The market awaits Intellinetics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 8.11% increase in the share price on the subsequent day.
Here's a look at Intellinetics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0</td>
<td>0.01</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.01</td>
<td>-0.09</td>
<td>0.02</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-13.0%</td>
<td>-7.000000000000001%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747076994_0.png" alt="eps graph" />
<h3>Intellinetics Share Price Analysis</h3>
Shares of Intellinetics were trading at $13.4994 as of May 09. Over the last 52-week period, shares are up 51.52%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/INLX/earnings">To track all earnings releases for Intellinetics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INLX

Uncovering Potential: Intellinetics's Earnings Preview

Artificial intelligence has <a href="https://www.benzinga.com/tech/25/05/45338301/zuckerberg-foresees-tech-industry-revolution-with-ai-an-ai-that-can-effectively-be-a-sort-of-midlevel-engineer">captured the imagination</a> of virtually every company in the tech world as the technology rapidly becomes more powerful. Perplexity, an AI startup and a potential threat to Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, was valued at $14 billion in its latest funding round.
What Happened: The company is in advanced talks with venture-capital firm Accel for a $500 million funding round that places the San Francisco-based company <a href="https://www.benzinga.com/news/25/04/44865115/figure-ai-shakes-silicon-valley-with-39-5b-valuation-200000-robots-promised-by-2029-beating-out-spacex-and-openai">among the most valuable</a> AI startups, <a href="https://www.wsj.com/tech/ai-startup-perplexitys-valuation-surges-to-14-billion-in-fresh-funding-round-26124482?msockid=21c662101c496b42343370ae1de86aaa">according</a> to The Wall Street Journal.
The company was valued at $9 billion in November 2024, representing an over 50% increase in valuation in the past six months. However, the $14 billion figure falls under the start-up&#8217;s desired $18 billion valuation in March, <a href="https://x.com/haydenfield/status/1921981248857084190">according</a> to CNBC&#8217;s Hayden Field.
Jeff Bezos and Japan&#8217;s SoftBank Group are among Perplexity&#8217;s past investors, according to Reuters.
Why it Matters: Perplexity is a search engine that delivers answers to any question by searching the web and compiling information from multiple sources. Unlike traditional search engines, it provides inline citations, allowing users to verify facts easily. Despite some enthusiasm, Perplexity faces many hurdles, including high infrastructure costs and concerns over the legality of its content.
Several reports have likened Perplexity to a <a href="https://www.benzinga.com/25/05/45311557/gene-munster-warns-googles-search-grip-is-slipping-as-chatgpt-alters-user-behavior-doj-turns-up-the-heat">rival of Google</a> as the latter experiences <a href="https://www.benzinga.com/25/05/45339953/apple-exec-says-iphone-users-are-ditching-google-search-now-chamath-palihaptiya-urges-the-tech-giant-to-stop-waiting-for-data-and-start-fighting-models-like-chatgpt">stagnant search query</a> growth. While the Mountain View, California-based company still maintains a dominant industry position with its search business, its market share sits at its lowest in decades.
OpenAI was <a href="https://www.benzinga.com/25/04/44580172/openai-finalizes-historic-40-billion-funding-round-valuing-company-at-300-billion-with-backing-from-softbank-and-microsoft">valued at $300 billion</a> in an April funding round. Elon Musk&#8216;s xAI, another tech industry newcomer, was <a href="https://www.benzinga.com/tech/25/03/44549314/elon-musk-acquires-his-own-social-media-platform-x-through-xai-in-33-billion-deal-says-combined-entity-now-worth-80-billion">valued at $80 billion</a> in March.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45355655/magnificent-seven-gain-700b-after-us-china-slash-tariffs-gold-crashes-whats-driving-markets-monday">Magnificent Seven Gain $700B After US-China Slash Tariffs, Gold Crashes: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Financing

GOOG

GOOGL

Perplexity's $14 Billion Valuation Ignites Google Search Engine Shakeup

Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Quoin Pharmaceuticals to report an earnings per share (EPS) of $-4.20.
Anticipation surrounds Quoin Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 3.17% increase in the share price the next day.
Here's a look at Quoin Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.43</td>
<td>-0.49</td>
<td>-0.61</td>
<td>-0.76</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.35</td>
<td>-0.47</td>
<td>-0.39</td>
<td>-1.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747076929_0.png" alt="eps graph" />
<h3>Tracking Quoin Pharmaceuticals's Stock Performance</h3>
Shares of Quoin Pharmaceuticals were trading at $6.19 as of May 09. Over the last 52-week period, shares are down 76.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/QNRX/earnings">To track all earnings releases for Quoin Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

QNRX

A Peek at Quoin Pharmaceuticals's Future Earnings

Last Wednesday, NeuroSense Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) said it scaled up its production of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">PrimeC to a commercial scale</a>.
PrimeC, NeuroSense&#8217;s lead drug candidate, is a novel extended-release oral formulation with a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
NeuroSense said it bolstered its supply chain by implementing comprehensive Chemistry, Manufacturing, and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45251140/neurosense-therapeutics-announces-successful-completion-of-commercial-manufacturing-scale-up-for-p" rel="noreferrer noopener">Controls (CMC) enhancements</a>.
Additionally, the company partnered with a global contract development and manufacturing organization (CDMO) that currently manufactures PrimeC clinical batches and will support its future commercial supply.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41571215/exclusive-nano-cap-neurosense-schedules-fda-meeting-to-advance-lead-program-and-marketing-applicatio" rel="noreferrer noopener">EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission</a>
Stability data support a shelf life of at least&nbsp;36 months at room temperature, and formulation IP granted in 2023 provides protection through 2042.
NeuroSense is working to advance discussions with Health Canada to pursue early market entry through the Notice of Compliance with Conditions (NOC/c) pathway.
Commercial forecasts suggest a potential peak annual revenue of $100–150 million in&nbsp;Canada.
D. Boral Capital initiated coverage on NeuroSense on Monday with a Buy rating and <a href="https://www.benzinga.com/quote/NRSN/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $14</a>.
Analyst Jason Kolbert says, &#8220;The mechanistic rationale is supported by both preclinical and translational research, positioning PrimeC as a multimodal therapy in a field still dominated by marginally effective monotherapies.&#8221;
D. Boral writes that the ongoing Phase 2b PARADIGM trial is designed to provide further validation and is expected to report topline results in the second half of 2025.
In April, NeuroSense shared new findings from its Phase&nbsp;2b&nbsp;PARADIGM clinical trial. The data highlights the impact of PrimeC on microRNA (miRNA) modulation, representing a significant development in understanding how the therapy may slow disease progression.
It reveals the consistent effect of PrimeC on altering the expression of miRNAs associated with ALS, aligning with the previously reported clinical benefits, including a 33% reduction in disease progression and a 58% improvement in survival rates observed with PrimeC treatment.
The analyst notes that NeuroSense is expanding its platform into Alzheimer&#8217;s and Parkinson&#8217;s disease, leveraging the same pathophysiologic targets with modified drug combinations. This modular approach could significantly broaden the company&#8217;s addressable market while maintaining development efficiency.
&#8220;We believe NeuroSense is at an inflection point where clinical proof-of-concept data, coupled with upcoming catalysts, could drive substantial value creation,&#8221; Kolbert adds.
In August 2024, NeuroSense Therapeutics said it was in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40596888/exclusive-neurosense-therapeutics-in-advanced-talks-with-several-multi-billion-dollar-pharma-comp" rel="noreferrer noopener">commercialize PrimeC for&nbsp;ALS</a>.
Price Action: NRSN stock is up 6.34% at $1.11 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a></li>
</ul>
Image via Shutterstock

Health Care

Initiation

Movers

NRSN

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Gevo to report an earnings per share (EPS) of $-0.08.
Investors in Gevo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 9.92% drop in the share price the following trading session.

<img src="https://www.benzinga.com/files/images/story/2025/1747076657_0.png" alt="eps graph" />
<h3>Performance of Gevo Shares</h3>
Shares of Gevo were trading at $1.16 as of May 09. Over the last 52-week period, shares are up 61.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Gevo</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Gevo.
A total of 3 analyst ratings have been received for Gevo, with the consensus rating being Buy. The average one-year price target stands at $9.72, suggesting a potential 737.93% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Green Plains, Clean Energy Fuels and REX American Resources, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Green Plains, with an average 1-year price target of $7.3, suggesting a potential 529.31% upside.</li>
<li>Analysts currently favor an Buy trajectory for Clean Energy Fuels, with an average 1-year price target of $4.33, suggesting a potential 273.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for REX American Resources, with an average 1-year price target of $50.0, suggesting a potential 4210.34% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Green Plains, Clean Energy Fuels and REX American Resources, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gevo</td>
<td>Buy</td>
<td>30.32%</td>
<td>$2.25M</td>
<td>-3.54%</td>
</tr>
<tr>
<td>Green Plains</td>
<td>Neutral</td>
<td>-18.02%</td>
<td>$6.15M</td>
<td>-6.14%</td>
</tr>
<tr>
<td>Clean Energy Fuels</td>
<td>Buy</td>
<td>2.31%</td>
<td>$23.57M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>REX American Resources</td>
<td>Buy</td>
<td>-15.66%</td>
<td>$17.57M</td>
<td>1.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gevo is positioned at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Gevo's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its equity holders.
<h3>Get to Know Gevo Better</h3>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
<h3>Financial Insights: Gevo</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Gevo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 30.32% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -308.89%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Gevo's ROE stands out, surpassing industry averages. With an impressive ROE of -3.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Gevo's ROA stands out, surpassing industry averages. With an impressive ROA of -2.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.14, Gevo adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/GEVO/earnings">To track all earnings releases for Gevo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GEVO

Insights Ahead: Gevo's Quarterly Earnings

MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ:&nbsp;MLGO), they announced today their research on quantum visual computing, exploring the integration of quantum computing with classical convolutional neural networks. They are developing a Quantum Convolutional Neural Network (QCNN) architecture to enhance the performance of traditional computer vision tasks using quantum mechanics principles.

MLGO

MicroAlgo Announces Research On Quantum Visual Computing, Exploring Integration Of Quantum Computing With Classical Convolutional Neural Networks

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that Nutex Health will report an earnings per share (EPS) of $-0.15. 
Nutex Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Nutex Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td>-0.24</td>
<td>-0.02</td>
<td>0</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>11.12</td>
<td>-1.72</td>
<td>-0.07</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>52.0%</td>
<td>9.0%</td>
<td>28.000000000000004%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<h3>Nutex Health Share Price Analysis</h3>
Shares of Nutex Health were trading at $120.73 as of May 09. Over the last 52-week period, shares are up 1638.17%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Observations about Nutex Health</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Nutex Health.
A total of 2 analyst ratings have been received for Nutex Health, with the consensus rating being Buy. The average one-year price target stands at $87.5, suggesting a potential 27.52% downside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Fulgent Genetics, Talkspace and Castle Biosciences, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Fulgent Genetics, with an average 1-year price target of $21.33, suggesting a potential 82.33% downside.</li>
<li>Analysts currently favor an Buy trajectory for Talkspace, with an average 1-year price target of $5.0, suggesting a potential 95.86% downside.</li>
<li>Analysts currently favor an Buy trajectory for Castle Biosciences, with an average 1-year price target of $36.33, suggesting a potential 69.91% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Fulgent Genetics, Talkspace and Castle Biosciences are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutex Health</td>
<td>Buy</td>
<td>269.77%</td>
<td>$141.63M</td>
<td>59.67%</td>
</tr>
<tr>
<td>Fulgent Genetics</td>
<td>Neutral</td>
<td>13.92%</td>
<td>$28.35M</td>
<td>-1.02%</td>
</tr>
<tr>
<td>Talkspace</td>
<td>Buy</td>
<td>7.11%</td>
<td>$21.53M</td>
<td>0.28%</td>
</tr>
<tr>
<td>Castle Biosciences</td>
<td>Buy</td>
<td>20.57%</td>
<td>$71.61M</td>
<td>-5.77%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nutex Health ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>All You Need to Know About Nutex Health</h3>
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
<h3>Financial Insights: Nutex Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Nutex Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 269.77% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Nutex Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 59.67%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Nutex Health's ROA stands out, surpassing industry averages. With an impressive ROA of 11.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.33, Nutex Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/NUTX/earnings">To track all earnings releases for Nutex Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NUTX

Earnings Preview For Nutex Health

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Capricor Therapeutics to report an earnings per share (EPS) of $-0.32.
Capricor Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.15, leading to a 17.51% increase in the share price the following trading session.
Here's a look at Capricor Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.36</td>
<td>-0.36</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.38</td>
<td>-0.35</td>
<td>-0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>18.0%</td>
<td>9.0%</td>
<td>9.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747076571_0.png" alt="eps graph" />
<h3>Market Performance of Capricor Therapeutics's Stock</h3>
Shares of Capricor Therapeutics were trading at $6.34 as of May 09. Over the last 52-week period, shares are up 37.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Capricor Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Capricor Therapeutics.
The consensus rating for Capricor Therapeutics is Buy, derived from 4 analyst ratings. An average one-year price target of $65.25 implies a potential 929.18% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Rigel Pharmaceuticals, with an average 1-year price target of $39.75, suggesting a potential 526.97% upside.</li>
<li>Analysts currently favor an Neutral trajectory for 2seventy bio, with an average 1-year price target of $5.0, suggesting a potential 21.14% downside.</li>
<li>Analysts currently favor an Buy trajectory for Abeona Therapeutics, with an average 1-year price target of $16.5, suggesting a potential 160.25% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-29.86%</td>
<td>$71.30M</td>
<td>-6.32%</td>
</tr>
<tr>
<td>Rigel Pharmaceuticals</td>
<td>Buy</td>
<td>80.58%</td>
<td>$48.92M</td>
<td>104.74%</td>
</tr>
<tr>
<td>2seventy bio</td>
<td>Neutral</td>
<td>-72.61%</td>
<td>$-5.92M</td>
<td>-8.89%</td>
</tr>
<tr>
<td>Abeona Therapeutics</td>
<td>Buy</td>
<td>0.00%</td>
<td>$0</td>
<td>-20.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Capricor Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas compared to its peers. However, it ranks in the middle for Return on Equity, suggesting a moderate level of profitability relative to others.
<h3>Unveiling the Story Behind Capricor Therapeutics</h3>
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
<h3>Breaking Down Capricor Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Capricor Therapeutics faced challenges, resulting in a decline of approximately -7.92% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Capricor Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -63.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Capricor Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.66%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.4%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Capricor Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/CAPR/earnings">To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

A Look Ahead: Capricor Therapeutics's Earnings Forecast

High-rolling investors have positioned themselves bearish on Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in U often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Unity Software. This is not a typical pattern.
The sentiment among these major traders is split, with 15% bullish and 61% bearish. Among all the options we identified, there was one put, amounting to $160,665, and 12 calls, totaling $633,463.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $26.0 for Unity Software over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Unity Software options trades today is 3609.5 with a total volume of 3,361.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Unity Software's big money trades within a strike price range of $20.0 to $26.0 over the last 30 days.
<h3>Unity Software 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747076478_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$6.55</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$26.00</td>
<td>$160.6K</td>
<td>0</td>
<td>251</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.0</td>
<td>$1.88</td>
<td>$2.0</td>
<td>$20.00</td>
<td>$99.6K</td>
<td>2.7K</td>
<td>302</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.01</td>
<td>$1.87</td>
<td>$1.9</td>
<td>$20.00</td>
<td>$95.0K</td>
<td>2.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.01</td>
<td>$1.87</td>
<td>$1.9</td>
<td>$20.00</td>
<td>$95.0K</td>
<td>2.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.25</td>
<td>$2.91</td>
<td>$3.09</td>
<td>$25.00</td>
<td>$77.1K</td>
<td>12.1K</td>
<td>261</td>
</tr>
</tbody>
</table>

<h3>About Unity Software</h3>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
Following our analysis of the options activities associated with Unity Software, we pivot to a closer look at the company's own performance.
<h3>Unity Software's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,940,477, the price of U is up by 4.82%, reaching $21.55.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>What The Experts Say On Unity Software</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $27.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Unity Software, targeting a price of $25. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Unity Software, which currently sits at a price target of $25. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Unity Software, which currently sits at a price target of $28. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Unity Software, targeting a price of $30. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Unity Software options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Unity Software's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bullish move on Pinterest. Our analysis of options history for Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) revealed 32 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 34% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $155,510, and 30 were calls, valued at $1,387,451.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $18.0 to $45.0 for Pinterest during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pinterest's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pinterest's substantial trades, within a strike price spectrum from $18.0 to $45.0 over the preceding 30 days.
<h3>Pinterest 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747076473_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$13.25</td>
<td>$13.0</td>
<td>$13.0</td>
<td>$25.00</td>
<td>$150.8K</td>
<td>656</td>
<td align="right">117</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.08</td>
<td>$27.00</td>
<td>$121.5K</td>
<td>1.5K</td>
<td align="right">430</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$12.45</td>
<td>$12.0</td>
<td>$12.1</td>
<td>$45.00</td>
<td>$121.0K</td>
<td>0</td>
<td align="right">200</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$15.0</td>
<td>$14.65</td>
<td>$14.8</td>
<td>$20.00</td>
<td>$74.0K</td>
<td>137</td>
<td align="right">100</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$4.65</td>
<td>$5.3</td>
<td>$27.50</td>
<td>$53.0K</td>
<td>2.1K</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h3>About Pinterest</h3>
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.
Having examined the options trading patterns of Pinterest, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Pinterest</h3>
<ul>
<li>With a volume of 24,914,740, the price of PINS is up 13.5% at $33.16. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What The Experts Say On Pinterest</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $40.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Pinterest, which currently sits at a price target of $36. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Pinterest, targeting a price of $41. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Pinterest, which currently sits at a price target of $45. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Pinterest with a target price of $38. 
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for Pinterest, targeting a price of $40. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pinterest with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

PINS

Pinterest Options Trading: A Deep Dive into Market Sentiment

Press Releases

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom

Contracts

Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Commodities

Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors

Comments

Ginkgo Bioworks Holdings

Actualités

Dernières nouvelles pour Ginkgo Bioworks Holdings (NYSE:DNA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL